Academic Journal
View in EDS
Linked Full Text

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors

Bibliographic Details
Title: A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
Authors: Kathryn E. Beckermann, MD, PhD, Christine M. Bestvina, MD, Badi El Osta, MD, Rachel E. Sanborn, MD, Hossein Borghaei, MD, Philip Edward Lammers, MD, MSCI, Giovanni Selvaggi, MD, Jennifer G. Whisenant, PhD, Ellen Heimann-Nichols, MBA, Lynne Berry, PhD, Chih-Yuan Hsu, PhD, Yu Shyr, PhD, Leora Horn, MD, MSc, MHPE, Heather Wakelee, MD, FASCO
Source: JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100619- (2024)
Publisher Information: Elsevier, 2024.
Publication Year: 2024
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Lung cancer, Thymic, Small cell, Anti-angiogenic, Nivolumab, PD-1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Introduction: Targeting the tumor microenvironment may enhance response to immunotherapy (immune checkpoint inhibitors) and improve outcomes for patients. This study tested the safety and efficacy of vorolanib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and c-KIT, in combination with programmed cell death protein 1 blockade using nivolumab for refractory thoracic malignancies. Methods: This single-arm multicenter study enrolled patients with extensive-stage SCLC, thymic carcinoma, and NSCLC, either naive or had progressed on previous chemotherapy or immune checkpoint inhibitors (either primary or acquired resistance). The primary objective of phase 1 was to determine the maximum tolerated dose, and the primary end point for each dose-expansion cohort was the objective response rate. Results: A total of 88 patients were enrolled in phase 1 (n = 11) and dose expansion (n = 77) cohorts. Transaminitis was dose-limiting and expansion proceeded with oral vorolanib 200 mg daily combined with intravenous nivolumab 240 mg every 2 weeks. The objective response rate per cohort were as follows: NSCLC naive 33% (five of 15, 95% confidence interval [CI]: 13%–60%), NSCLC primary refractory 5.9% (one of 17, 95% CI: 0%–17.6%), NSCLC acquired resistance 11.1% (two of 18, 95% CI: 0%–27.8%); SCLC 0% (zero of 18), and thymic carcinoma 11% (one of nine, 95% CI: 0%–33%). Disease control rate ranged from 11.1% in SCLC (two of 18, 0%–27.8%) to 66.7 % in thymic carcinoma (six of nine, 95% CI: 33.3%–100%). The most common adverse events were fatigue (32%), aspartate transaminase (27%) and alanine transaminase elevation (25%), and diarrhea (19%). Transaminitis was more common in patients with thymic carcinoma than other tumors. Conclusions: Vorolanib plus nivolumab had a manageable safety profile and may have clinical benefits in various thoracic malignancies. The disease control rate in thymic malignancies warrants further assessment.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2666-3643
Relation: http://www.sciencedirect.com/science/article/pii/S2666364323001625; https://doaj.org/toc/2666-3643
DOI: 10.1016/j.jtocrr.2023.100619
Access URL: https://doaj.org/article/c6b067ef1dff4f2782f2f6840a59c659
Accession Number: edsdoj.6b067ef1dff4f2782f2f6840a59c659
Database: Directory of Open Access Journals
FullText Links:
  – Type: other
    Url: https://resolver.ebsco.com:443/public/rma-ftfapi/ejs/direct?AccessToken=47F3BA529D800397E8CC&Show=Object
Text:
  Availability: 0
CustomLinks:
  – Url: https://www.doi.org/10.1016/j.jtocrr.2023.100619?
    Name: ScienceDirect (all content)-s8985755
    Category: fullText
    Text: View record from ScienceDirect
    MouseOverText: View record from ScienceDirect
  – Url: https://resolver.ebsco.com/c/xy5jbn/result?sid=EBSCO:edsdoj&genre=article&issn=26663643&ISBN=&volume=5&issue=2&date=20240201&spage=&pages=&title=JTO Clinical and Research Reports&atitle=A%20Phase%201%2F2%20Study%20to%20Evaluate%20the%20Safety%20and%20Activity%20of%20Nivolumab%20in%20Combination%20With%20Vorolanib%2C%20a%20Vascular%20Endothelial%20Growth%20Factor%20Tyrosine%20Kinase%20Inhibitor%2C%20in%20Patients%20With%20Refractory%20Thoracic%20Tumors&aulast=Kathryn%20E.%20Beckermann%2C%20MD%2C%20PhD&id=DOI:10.1016/j.jtocrr.2023.100619
    Name: Full Text Finder (for New FTF UI) (s8985755)
    Category: fullText
    Text: Find It @ SCU Libraries
    MouseOverText: Find It @ SCU Libraries
  – Url: https://doaj.org/article/c6b067ef1dff4f2782f2f6840a59c659
    Name: EDS - DOAJ (s8985755)
    Category: fullText
    Text: View record from DOAJ
    MouseOverText: View record from DOAJ
Header DbId: edsdoj
DbLabel: Directory of Open Access Journals
An: edsdoj.6b067ef1dff4f2782f2f6840a59c659
RelevancyScore: 995
AccessLevel: 3
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 995.390563964844
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Kathryn+E%2E+Beckermann%2C+MD%2C+PhD%22">Kathryn E. Beckermann, MD, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Christine+M%2E+Bestvina%2C+MD%22">Christine M. Bestvina, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Badi+El+Osta%2C+MD%22">Badi El Osta, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Rachel+E%2E+Sanborn%2C+MD%22">Rachel E. Sanborn, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Hossein+Borghaei%2C+MD%22">Hossein Borghaei, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Philip+Edward+Lammers%2C+MD%2C+MSCI%22">Philip Edward Lammers, MD, MSCI</searchLink><br /><searchLink fieldCode="AR" term="%22Giovanni+Selvaggi%2C+MD%22">Giovanni Selvaggi, MD</searchLink><br /><searchLink fieldCode="AR" term="%22Jennifer+G%2E+Whisenant%2C+PhD%22">Jennifer G. Whisenant, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Ellen+Heimann-Nichols%2C+MBA%22">Ellen Heimann-Nichols, MBA</searchLink><br /><searchLink fieldCode="AR" term="%22Lynne+Berry%2C+PhD%22">Lynne Berry, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Chih-Yuan+Hsu%2C+PhD%22">Chih-Yuan Hsu, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Yu+Shyr%2C+PhD%22">Yu Shyr, PhD</searchLink><br /><searchLink fieldCode="AR" term="%22Leora+Horn%2C+MD%2C+MSc%2C+MHPE%22">Leora Horn, MD, MSc, MHPE</searchLink><br /><searchLink fieldCode="AR" term="%22Heather+Wakelee%2C+MD%2C+FASCO%22">Heather Wakelee, MD, FASCO</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: JTO Clinical and Research Reports, Vol 5, Iss 2, Pp 100619- (2024)
– Name: Publisher
  Label: Publisher Information
  Group: PubInfo
  Data: Elsevier, 2024.
– Name: DatePubCY
  Label: Publication Year
  Group: Date
  Data: 2024
– Name: Subset
  Label: Collection
  Group: HoldingsInfo
  Data: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
– Name: Subject
  Label: Subject Terms
  Group: Su
  Data: <searchLink fieldCode="DE" term="%22Lung+cancer%22">Lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Thymic%22">Thymic</searchLink><br /><searchLink fieldCode="DE" term="%22Small+cell%22">Small cell</searchLink><br /><searchLink fieldCode="DE" term="%22Anti-angiogenic%22">Anti-angiogenic</searchLink><br /><searchLink fieldCode="DE" term="%22Nivolumab%22">Nivolumab</searchLink><br /><searchLink fieldCode="DE" term="%22PD-1%22">PD-1</searchLink><br /><searchLink fieldCode="DE" term="%22Neoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22RC254-282%22">RC254-282</searchLink>
– Name: Abstract
  Label: Description
  Group: Ab
  Data: Introduction: Targeting the tumor microenvironment may enhance response to immunotherapy (immune checkpoint inhibitors) and improve outcomes for patients. This study tested the safety and efficacy of vorolanib, a novel tyrosine kinase inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and c-KIT, in combination with programmed cell death protein 1 blockade using nivolumab for refractory thoracic malignancies. Methods: This single-arm multicenter study enrolled patients with extensive-stage SCLC, thymic carcinoma, and NSCLC, either naive or had progressed on previous chemotherapy or immune checkpoint inhibitors (either primary or acquired resistance). The primary objective of phase 1 was to determine the maximum tolerated dose, and the primary end point for each dose-expansion cohort was the objective response rate. Results: A total of 88 patients were enrolled in phase 1 (n = 11) and dose expansion (n = 77) cohorts. Transaminitis was dose-limiting and expansion proceeded with oral vorolanib 200 mg daily combined with intravenous nivolumab 240 mg every 2 weeks. The objective response rate per cohort were as follows: NSCLC naive 33% (five of 15, 95% confidence interval [CI]: 13%–60%), NSCLC primary refractory 5.9% (one of 17, 95% CI: 0%–17.6%), NSCLC acquired resistance 11.1% (two of 18, 95% CI: 0%–27.8%); SCLC 0% (zero of 18), and thymic carcinoma 11% (one of nine, 95% CI: 0%–33%). Disease control rate ranged from 11.1% in SCLC (two of 18, 0%–27.8%) to 66.7 % in thymic carcinoma (six of nine, 95% CI: 33.3%–100%). The most common adverse events were fatigue (32%), aspartate transaminase (27%) and alanine transaminase elevation (25%), and diarrhea (19%). Transaminitis was more common in patients with thymic carcinoma than other tumors. Conclusions: Vorolanib plus nivolumab had a manageable safety profile and may have clinical benefits in various thoracic malignancies. The disease control rate in thymic malignancies warrants further assessment.
– Name: TypeDocument
  Label: Document Type
  Group: TypDoc
  Data: article
– Name: Format
  Label: File Description
  Group: SrcInfo
  Data: electronic resource
– Name: Language
  Label: Language
  Group: Lang
  Data: English
– Name: ISSN
  Label: ISSN
  Group: ISSN
  Data: 2666-3643
– Name: NoteTitleSource
  Label: Relation
  Group: SrcInfo
  Data: http://www.sciencedirect.com/science/article/pii/S2666364323001625; https://doaj.org/toc/2666-3643
– Name: DOI
  Label: DOI
  Group: ID
  Data: 10.1016/j.jtocrr.2023.100619
– Name: URL
  Label: Access URL
  Group: URL
  Data: <link linkTarget="URL" linkTerm="https://doaj.org/article/c6b067ef1dff4f2782f2f6840a59c659" linkWindow="_blank">https://doaj.org/article/c6b067ef1dff4f2782f2f6840a59c659</link>
– Name: AN
  Label: Accession Number
  Group: ID
  Data: edsdoj.6b067ef1dff4f2782f2f6840a59c659
PLink https://login.libproxy.scu.edu/login?url=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.6b067ef1dff4f2782f2f6840a59c659
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jtocrr.2023.100619
    Languages:
      – Text: English
    Subjects:
      – SubjectFull: Lung cancer
        Type: general
      – SubjectFull: Thymic
        Type: general
      – SubjectFull: Small cell
        Type: general
      – SubjectFull: Anti-angiogenic
        Type: general
      – SubjectFull: Nivolumab
        Type: general
      – SubjectFull: PD-1
        Type: general
      – SubjectFull: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
        Type: general
      – SubjectFull: RC254-282
        Type: general
    Titles:
      – TitleFull: A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kathryn E. Beckermann, MD, PhD
      – PersonEntity:
          Name:
            NameFull: Christine M. Bestvina, MD
      – PersonEntity:
          Name:
            NameFull: Badi El Osta, MD
      – PersonEntity:
          Name:
            NameFull: Rachel E. Sanborn, MD
      – PersonEntity:
          Name:
            NameFull: Hossein Borghaei, MD
      – PersonEntity:
          Name:
            NameFull: Philip Edward Lammers, MD, MSCI
      – PersonEntity:
          Name:
            NameFull: Giovanni Selvaggi, MD
      – PersonEntity:
          Name:
            NameFull: Jennifer G. Whisenant, PhD
      – PersonEntity:
          Name:
            NameFull: Ellen Heimann-Nichols, MBA
      – PersonEntity:
          Name:
            NameFull: Lynne Berry, PhD
      – PersonEntity:
          Name:
            NameFull: Chih-Yuan Hsu, PhD
      – PersonEntity:
          Name:
            NameFull: Yu Shyr, PhD
      – PersonEntity:
          Name:
            NameFull: Leora Horn, MD, MSc, MHPE
      – PersonEntity:
          Name:
            NameFull: Heather Wakelee, MD, FASCO
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 02
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 26663643
          Numbering:
            – Type: volume
              Value: 5
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: JTO Clinical and Research Reports
              Type: main
ResultId 1